PRESS RELEASE: Chief Counsel Leaves HHS/FDA for Private Sector

Chief Counsel Leaves HHS/FDA for Private Sector

Jeffrey Senger to Fill Post on Acting Basis

Sheldon Bradshaw, Associate General Counsel/Chief Counsel of the Food & Drug Division of the U.S. Department of Health and Human Services' Office of the General Counsel has announced that he will leave the department, effective Sept. 12, 2007 to return to the private sector.

Bradshaw joined HHS as Associate General Counsel for the Food and Drug Division in April 2005. In that position, he provided legal advice to FDA's senior leadership on a number of significant policy matters, including the agency's drug and food safety initiatives.

Bradshaw also formulated the legal basis for numerous regulations and guidances critical to the agency's vital public health mission, including the new drug and biologic products labeling rule, enforced the requirements of the Food, Drug and Cosmetic Act in federal court, and defended the agency's programs when they were challenged.

"Leadership and insight from the Office of the General Counsel's Food and Drug Division is essential to FDA's operations, and the agency is well-served by the talented individuals in this office," said Andrew C. von Eschenbach, M.D., Commissioner, Food and Drugs. "I have greatly appreciated Sheldon's wise legal counsel, steadfast support and tireless dedication, and wish him well as he returns to the private sector."

Jeffrey Senger, the current Deputy Associate General Counsel has become the Acting Associate General Counsel until a permanent replacement is appointed.

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.